SarcopeniaOncologyPhysical InactivityToxicity Due to Chemotherapy
Investigational drug(s) / intervention(s)
Sarcopenia diagnostic test
Sarcopenia diagnostic test: the study-specific measurements for the assessment of sarcopenia (impedancemetry, grip strength and chair rise test) as well as the distribution of actimeters to patients.
Study summary
The goal of this clinical trial is to learn about the effect of sarcopenic status on the occurrence of treatment-related toxicity during the first course of anti-cancer treatment in several types of cancers.
The main question it aims to answer is :
Is sarcopenia a predictive marker for the occurrence of toxicity in the initial phase of cancer treatment?
The evaluation will focus on the body composition of the participants, assessed by impedancemetry, and on their muscular performance by standardized physical tests.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients over 18 years old
* Patient with a diagnosis of a histologically proven solid malignant tumor with an indication for systemic treatment during initial treatment.
* CT/PET performed within 45 days before initiation of systemic treatment.
* Patient able to sign informed consent for participation in the study
* Patient affiliated to a social security system
Exclusion Criteria:
* History of cancer in the five years preceding inclusion other than localized skin or cervical cancers.
* Patient with cancer not requiring systemic treatment.
* Pregnant women.
* Patient with a pace maker or defibrillator
* Patient deprived of liberty or benefiting from a legal protection measure
Primary outcome measure(s)
Event-free survival according to sarcopenic statut — Day 1 of the first treatment cycle to Day 1 of the second treatment cycle, approx. 4 weeks Event-free survival will be defined as the time from the date of the experimental visit to the date of the first documented dose-limiting toxicity. Participants who will not experience an event as of the time of data cut-off (beginning of the second cycle of treatment) or who stopped study participation before the end of the follow-up, will be right-censored. The measure will be analyzed using a COX multivariate model with event incidence rate as dependant variable and the sarcopenia statut as independent variable.
Trial sites (1)
Facility
City
Region
Status
Centre Hospitalier Metropole Savoie
Chambéry
France
Recruiting
More Centre Hospitalier Metropole Savoie trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
